Japanese collaboration agreement extended to allow final evaluation of performance on clinical samples

In December 2019, AcouSort announced that the company had signed an agreement with a major Japanese industrial player regarding the lease of one AcouWash system and accompanying application support. The system has been used for sample preparation in an R&D project aiming to develop and evaluate the potential of a new diagnostic assay. The evaluation is now in its final phase, where the new assay will be tested using clinical samples.

Over the past years, AcouSort has worked very closely with the Japanese company’s research team and successfully helped them to optimize their cell separation application required to enable the development of the new diagnostic test. During 2022, AcouSort and the Japanese partner finalized the application optimization of the sample preparation part. In parallel, the Japanese team finalized the development of the assay. The Japanese company has now extended the lease of the AcouWash system to evaluate the complete assay workflow on clinical samples. Once this evaluation is finalized, the Japanese company will start an internal review process to evaluate the business potential and decide whether to initiate a product development project.

The company has been very satisfied with the AcouWash sample preparation, which gives a higher sample quality and is significantly more stable than the centrifugation-based method they initially used.

“At AcouSort, we have been very happy with this great collaboration with a world-leading life science company. That the Japanese company has chosen to work with our technology in their assay development, and that the project now has reached the phase where clinical samples will be evaluated, is a great seal of approval. This project is in-line with our long-term strategy; to establish our acoustofluidic technology as the gold standard for providing integrated sample preparation in diagnostic and therapeutic instrumentation. ,” says AcouSort’s CEO Torsten Freltoft.

For further information on AcouSort, please contact:

Torsten Freltoft, CEO

E-mail: [email protected]

About AcouSort

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company’s products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company’s products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company’s commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company’s research instruments. With the help of the company’s products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is Erik Penser Bank, 08-463 83 00, mail to: [email protected] Erik Penser Bank AB (publ), Apelbergsgatan 27, Box 7405, 103 91 Stockholm.

< | >